All articles by Staff Writer
Staff Writer
MEDICA 2023 + COMPAMED 2023: “Where Healthcare is going” – the leading motif is reflected in a wide variety of formats
The entire value chain of medical care, product development and manufacture in focus at one location
Roche’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Tecentriq® SC (atezolizumab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain. It will be provided by the National Health Service (NHS) England. Injecting Tecentriq subcutaneously (under the skin) takes approximately seven minutes, compared with 30-60 minutes for intravenous (IV) infusion. Tecentriq SC will be available to patients in Great Britain for all indications in which the IV formulation of Tecentriq has been previously approved, including certain types of lung, bladder, breast and liver cancer.2
Trisol announces successful implants of its Transcatheter Tricuspid Valve in the US
Two implants were successfully conducted as part of the FDA approved Early Feasibility Study in the United States
Trialogics Opens London Office, Advancing Remote Device Management Services for Clinical Trials
Trialogics, a leading clinical trial software and services company, providing eConsent, IRT (RTSM), and eCOA, announced today that it is growing its overall services by expanding their Remote Device Management capabilities.
IVI and the Madagascar Institute for Vaccine Research launch typhoid conjugate vaccine campaign for infants and children
The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, and the Madagascar Institute for Vaccine Research (MIVR) at the University of Antanararivo held a ceremony today to launch a mass vaccination campaign against typhoid in the Arivonimamo and Antananarivo-Atsimondrano districts of Madagascar.
TB Alliance Announces Partnership with Remington Pharmaceuticals to Commercialize New Therapy for Drug-Resistant Forms of TB in Pakistan
Non-profit drug developer partners with leading manufacturer of medicine in Pakistan
MediCardia integrates wearable ECG for atrial fibrillation care
This integration claims to streamline AF care through remote monitoring and virtual health services.
TNAA acquires Stogo to address healthcare staffing shortage
Stogo, set up by Acute Care Hospital executives, helps resolve staff shortfall and scheduling hurdles faced by health systems.
Polpharma Biologics Announces FDA Approval of Tyruko® – First And Only Approved Biosimilar to Tysabri®* for Relapsing Forms of Multiple Sclerosis
Polpharma Biologics, an international biotech company dedicated to the development and manufacture of biosimilars, announced today that the U.S. Food and Drug Administration (FDA) is the first regulatory body worldwide to approve the use of Tyruko® (natalizumab-sztn) – a new biosimilar for the treatment of relapsing forms of multiple sclerosis (MS). Approval of Tyruko® by the European Medicines Agency is also expected imminently.
Genetic Signatures Announces Strategic Partnership with Integrated Gulf Biosystems for Expanded Market Reach in the Middle East
Genetic Signatures, a leading innovator in molecular diagnostics, is pleased to announce a new channel partner in the Middle East, Integrated Gulf Biosystems (IGB). With IGB’s headquarters in Dubai, the exclusive agreement allows Genetic Signatures to tap into the promising market of United Arab Emirates, Kingdom of Saudi Arabia, Bahrain and Qatar. This partnership is a significant step forward in Genetic Signatures’ mission to expand its market presence in the Middle East, providing clinical diagnostic laboratories access to its patented 3base® technology, and syndromic testing solutions for infectious diseases.